Merck Stock Down More Than 14% in 6 Months: Buy, Sell or Hold?

Merck's (MRK) stock has declined 14.4% in the past six months against an increase of 9.7% for the Large Cap Pharmaceuticals industry. The stock has also underperformed the sector and the S&P 500 Index, as seen in the chart below. The stock is also trading below its 200- and 50-day moving averages. Merck Stock Underperforms Industry, Sector & S&P 500 Image Source: Zacks Investment Research Merck boasts more than six blockbuster drugs in its portfolio, with blockbuster PD-L1 inhibitor Keytruda being the key t ...